Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Circulating Tumor DNA (ctDNA) for Plasma Genotyping and Disease Monitoring in ALK-Positive Anaplastic Lymphoma (ALK+ALCL): A Proof of Concept Study

Damien Vasseur, Samuel Abbou, Ludovic Lacroix, Laurence Lamant, Pata-Merci Noémie, David Sibon, Francesco Facchinetti, Marc Deloger, Floriane Braye, Veronique Minard-Colin, Laurence Brugières, Etienne Rouleau, Luc Friboulet, Charlotte Rigaud

Blood (2023) 142 (Supplement 1): 4375.

https://doi.org/10.1182/blood-2023-185808

Published: 2023

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

Journal Articles

Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa

Blood (2022) 140 (Supplement 1): 1082–1084.

https://doi.org/10.1182/blood-2022-166228

Published: 2022

Journal Articles

The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study

Blood (2022) 140 (Supplement 1): 3680–3682.

https://doi.org/10.1182/blood-2022-170841

Published: 2022

Journal Articles

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Blood (2022) 140 (Supplement 1): 2302–2305.

https://doi.org/10.1182/blood-2022-165217

Published: 2022

Journal Articles

The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma

David Sibon, Sherine Khater, Julie Bruneau, Chantal Brouzes, Ludovic Lhermitte, Thierry Jo Molina, Guillaume Cartron, Veronique Morel, Georgia Malamut, Adrien Chauchet, Franck Morschhauser, Baptiste Perard, Jean-Michel Boulet, Anne-Cécile Gauchy, Nadine Cerf-Bensussan, Elizabeth A. Macintyre, Vahid Asnafi, Christophe Cellier, Olivier Hermine

Blood (2021) 138 (Supplement 1): 136.

https://doi.org/10.1182/blood-2021-153709

Published: 2021

Journal Articles

Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

Blood (2021) 138 (Supplement 1): 232.

https://doi.org/10.1182/blood-2021-147863

Published: 2021

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Adults with Primary Mediastinal B Cells Lymphoma (PMBCL): A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and the Lymphoma Study Association (LYSA) Group

Blood (2021) 138 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2021-146857

Published: 2021

Journal Articles

Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

Blood (2021) 138 (Supplement 1): 620.

https://doi.org/10.1182/blood-2021-150953

Published: 2021

Journal Articles

Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas

Blood (2021) 138 (Supplement 1): 809.

https://doi.org/10.1182/blood-2021-150034

Published: 2021

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Blood (2021) 137 (17): 2307–2320.

https://doi.org/10.1182/blood.2020008750

Published: 2021

Includes: Supplemental data

Journal Articles

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-139224

Published: 2020

Journal Articles

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Christiane Copie Bergman, MDPhD, Elodie Bohers, PhD, Peggy Dartigues-Cuillères, MD, Pierre-Julien Viailly, Philippe Ruminy, PhD, Vinciane Marchand, Marie-Helene Delfau-Larue, Corinne Haioun, MDPhD, Cyrielle Robe, Elsa Poullot, MD, Steven Le Gouill, MD PhD, Yannick Le Bris, PharmD, Céline Bossard, MD, Anne Moreau, MD, Vincent Ribrag, MD, Valérie Camara-clayette, PhD, Cyril Quivoron, PhD, Gilles Salles, MDPhD, Sophie Cotteret, MD PhD, Pierre Sujobert, MD PhD, Alexandra Traverse-Glehen, MD PhD, Claire Mauduit, Pascaline Etancelin, Sarah Huet, Liana Veresezan, MD, Krimo Bouabdallah, MD, Marie Parrens, MD, Audrey Gros, PhD, Samuel Amintas, David Sibon, MD PhD, Ludovic Lhermitte, MD PhD, Thomas Steimle, Sophie Kaltenbach, Bettina Fabiani, MD, Camille Laurent, MD PhD, Barbara Burroni, Laurent Martin, MD PhD, Thierry Jo Molina, MDPhD, Lysa LYSARC study group, Fabrice Jardin, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141953

Published: 2020

Journal Articles

Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-138666

Published: 2020

Journal Articles

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Blood (2019) 134 (Supplement_1): 2887.

https://doi.org/10.1182/blood-2019-129532

Published: 2019

Journal Articles

Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin

Pierre-Edouard Debureaux, Delphine Le Febvre de Nailly, Emmanuelle Tavernier, MD, Manel Bedoui, MD, Frederique Kuhnowski, MD, Jerome Tamburini, MD PhD, Luc Mathieu Fornecker, Herve Tilly, MD, David Sibon, MD PhD, Marie-Pierre Moles, Sylvie Glaisner, MD, Jean Philippe Richardet, MD PhD, Sebastien Mule, MD PhD, Julien Calderaro, MD, Corinne Haioun, MD, Jehan Dupuis, MD

Blood (2018) 132 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2018-99-110728

Published: 2018

Journal Articles

NKp46 Is a Useful Diagnostic Biomarker in Gastrointestinal T-Cell Lymphoproliferative Diseases and Constitutes a Therapeutic Target. a Celac Network Study

Morgane Cheminant, MD, Julie Bruneau, MD PhD, Georgia Malamut, MD PhD, David Sibon, Nicolas Guegan, Sascha Cording, PhD, Amélie Trinquand, MD PhD, Nicole Brousse, MD PhD, Sherine Khater, MD, Elizabeth A. Macintyre, PhD FRCP, FRCPath, Vahid Asnafi, MD PhD, Laurent Pouyet, PhD, Florence Lhospice, PharmD, Thierry Jo Molina, MDPhD, Bertrand Meresse, PhD, Christophe Cellier, MD PhD, Nadine Cerf-Bensussan, MD PhD, Olivier Hermine, MD PhD

Blood (2017) 130 (Supplement 1): 2820.

https://doi.org/10.1182/blood.V130.Suppl_1.2820.2820

Published: 2017

Journal Articles

Systemic ALK-Positive Anaplastic Large-Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults

David Sibon, MD PhD, Dinh-Phong Nguyen, MD, Norbert Schmitz, MD, Ritsuro Suzuki, MD PhD, Andrew L Feldman, MD, Remy Gressin, MD, Laurence Lamant, MD PhD, Dennis D. Weisenburger, MD, Shigeo Nakamura, MD PhD, Marita Ziepert, PhD, Matthew J Maurer, MS, Martin Bast, James O. Armitage, MD, Julie M. Vose, MDMBA, Herve Tilly, Jean-Philippe Jais, MD PhD, Kerry J Savage, MD

Blood (2017) 130 (Supplement 1): 1514.

https://doi.org/10.1182/blood.V130.Suppl_1.1514.1514

Published: 2017

Journal Articles

Clonal B-Cell Lymphocytosis with Marginal Zone Features and Splenic Marginal Zone Lymphoma Share a Similar Cytogenetic and Mutational Profile

Paul Legendre, MD, Olivier Kosmider, PharmD, PhD, Coralie Derrieux, PharmD, Nicolas Chapuis, PharmD, PhD, Isabelle Radford-Weiss, PharmD, Hélène Guermouche, Barbara Burroni, MD, Julie Bruneau, MD PhD, Bénédicte Deau, MD, Richard Delarue, MD, Olivier Hermine, MD PhD, Didier Bouscary, MD PhD, David Sibon, MD PhD

Blood (2016) 128 (22): 2962.

https://doi.org/10.1182/blood.V128.22.2962.2962

Published: 2016

NARROW

Circulating Tumor DNA (ctDNA) for Plasma Genotyping and Disease Monitoring in ALK-Positive Anaplastic Lymphoma (ALK+ALCL): A Proof of Concept Study

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa

The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma

Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Adults with Primary Mediastinal B Cells Lymphoma (PMBCL): A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and the Lymphoma Study Association (LYSA) Group

Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin

NKp46 Is a Useful Diagnostic Biomarker in Gastrointestinal T-Cell Lymphoproliferative Diseases and Constitutes a Therapeutic Target. a Celac Network Study

Systemic ALK-Positive Anaplastic Large-Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults

Clonal B-Cell Lymphocytosis with Marginal Zone Features and Splenic Marginal Zone Lymphoma Share a Similar Cytogenetic and Mutational Profile

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only